Takeda Pharmaceuticals USA and Cognition Kit have demonstrated the use of an Apple Watch wearable to monitor and evaluate cognition and mood in patients suffering from major depressive disorder (MDD).

Cognition Kit, a joint venture between Cambridge Cognition and Ctrl Group, designed the Apple Watch application (app) to facilitate patient assessment and monitoring outside of the lab.

The patients were found to be 95% compliant with mood evaluation and 96% for cognition monitoring on a daily basis with the wearable device.

The prospective observational study involved administration of brief cognitive and mood tests on an Apple Watch for 30 subjects aged 18-65 years and prescribed with antidepressant monotherapy.

Co-primary objectives of the study included feasibility and compliance of mood and cognitive measures on wearable technology, and comparison of the measures with standard neuropsychological tests and patient-reported outcomes on the symptoms of depression.

“The patients were found to be 95% compliant with mood evaluation and 96% for cognition monitoring on a daily basis with the wearable device.”

The abbreviated assessments through the wearable device were comparable with objective Cambridge Neuropsychological Test Automated Battery (CANTAB) cognitive tests and full-length PHQ-9 and PDQ-D patient-reported outcomes carried out in the first, third and sixth weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the results did not indicate any adverse events during the study period.

Takeda Pharmaceuticals USA external partnerships vice-president Nicole Mowad-Nassar said: “Technology may allow us to create real-time objective measurements for assessing effects in depression that could transform patient care by increasing our ability to estimate clinical conditions and support earlier engagement between the patient and clinician.

“We are encouraged by the study results and look forward to learning more about the intersection of technology and healthcare.”